ROCKVILLE, Md., June 26, 2012 (CRWENewswire) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceuticals company, received a tentative approval letter from the Food & Drug Administration (the “FDA”) for Trokendi XR(TM), a once-daily extended release formulation of topiramate (formerly known as SPN-538). The letter states that the FDA completed its review of the Trokendi XR [...]
↧
